Last $2.41 USD
Change Today -0.12 / -4.74%
Volume 1.2M
GERN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 11:48 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$2.51
Previous Close
$2.53
Day High
$2.53
Day Low
$2.40
52 Week High
11/7/13 - $7.36
52 Week Low
08/7/13 - $1.20
Market Cap
378.2M
Average Volume 10 Days
3.6M
EPS TTM
$-0.26
Shares Outstanding
156.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

46 Employees
Last Reported Date: 03/17/14
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $569.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Executive Vice President of Portfolio and All...
Total Annual Compensation: $341.6K
Executive Vice President of Technical Operati...
Total Annual Compensation: $367.4K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $302.2K
Compensation as of Fiscal Year 2013.

geron corp (GERN) Key Developments

Geron Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM

Geron Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

Pomerantz LLP Files Class Action Lawsuit Against Geron Corporation and Certain of its Officers

Pomerantz LLP announced the filing of a class action lawsuit against Geron Corporation and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive. This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company's business, operations, prospects and performance. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that persistent low-grade LFT abnormalities had been observed in the Phase 2 study of imetelstat in ET/PV patients; (2) that there was a potential risk of chronic liver injury following long-term exposure to imetelstat; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company and the prospects for imetelstat lacked any reasonable basis and/or were materially false and misleading at all relevant times. On March 12, 2014, Geron disclosed that it had received verbal notice from the U.S. Food and Drug Administration that its Investigational New Drug ("IND") application for imetelstat had been placed on full clinical hold, affecting all ongoing Company sponsored clinical trials. A full clinical hold is an order that the FDA issues to a trial sponsor to suspend an ongoing clinical trial or delay a proposed trial. According to the Company, the FDA indicated that the clinical hold was due to the occurrence of persistent low-grade liver function test abnormalities observed in the Phase 2 study of imetelstat in ET/PV patients and the potential risk of chronic liver injury following long-term exposure to imetelstat. Also, Geron disclosed that the FDA expressed concern about whether these LFT abnormalities were reversible. As a result, Geron informed investors that the clinical hold would affect the remaining eight patients in the Company's Phase 2 study in essential thrombocythemia or polycythemia vera, and the remaining two patients in the company's Phase 2 study in multiple myeloma. Also, the Company indicated that a planned Phase 2 clinical trial in myelofibrosis would likely be delayed due to the clinical hold. On this news, shares of Geron declined $2.71 per share, over 61%, to close at $1.69 per share on March 12, 2014.

Geron Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014; Provides Interest Income Guidance for 2014

Geron reported unaudited earnings results for the first quarter ended March 31, 2014. For the first quarter of 2014, the company reported operating revenues of $474,000 compared to $765,000 for the comparable 2013 period. Net loss for the first quarter of 2014 was $8.4 million or $0.06 per share, compared to $11.9 million or $0.09 per share, for the comparable 2013 period. Revenues for the first quarter of 2014 and 2013 included royalty and license fee revenues under various agreements. Interest and other income for the first quarter of 2014 was $83,000, compared to $81,000 for the comparable 2013 period. Loss from operations was $8.7 million against $12 million of prior year period. The company expects interest income to be higher in 2014 than in 2013 due to higher cash and investment balances.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $2.41 USD -0.12

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GERN.
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.